Michelle began working at Ra Pharma in 2011 as an assay development scientist in the Target Biology group. Michelle’s initial role in the company was to design and perform the cell-based and biochemical assays needed for all projects. As Ra Pharma grew and identified a lead project, Michelle’s role grew to developing the pharmacodynamic assays needed for the animal studies. She then went on to design and oversee the validation of these assays for use in human clinical trials. Michelle’s career at Ra Pharma transitioned into the Translational Sciences group and now into the Clinical Development group where she is the Senior Manager for Clinical Science & Biomarker Development. Michelle is currently responsible for the pharmacodynamic, pharmacokinetic, pharmacogenomic and biomarker data across all completed and current Phase 1, Phase 2 and Phase 3 clinical trials at Ra Pharma for their C5 inhibitor, zilucoplan.